This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I protocol to evaluate the safety and tolerability of JVRS-100, a cationic lipid DNA complex (CLDC), for the treatment of patients with relapsed/refractory leukemia. This currently has a dismal prognosis. JVRS-100 consists of complexes of cationic lipid and plasmid DNA without a gene insert (non-coding DNA) which are potent activators of innate and adaptive immunity, induce NK, T and B cell activation, and stimulate the secretion of interferon-?, interferon-?, IL-12 and other cytokines. This is a 2 stage Phase I trial. In stage 1, an accelerated titration schema will be followed with one patient at each dose level. Stage 2 will commence after a dose limiting toxicity (DLT) is observed in stage 1 or after the maximum dose for stage 1 is reached. Stage 2 will follow a modified Fibonacci schema with 3-6 subjects at each dose level until a Recommended Phase 2 Dose (RP2D) is determined. The cohort will then be expanded to a maximum of 12 patients to more fully evaluate the RP2D.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR010732-15
Application #
7951291
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2009-04-01
Project End
2010-03-31
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
15
Fiscal Year
2009
Total Cost
$4,160
Indirect Cost
Name
Pennsylvania State University
Department
Type
Schools of Medicine
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033
Lieberman, Jay L; DE Souza, Mary Jane; Wagstaff, David A et al. (2018) Menstrual Disruption with Exercise Is Not Linked to an Energy Availability Threshold. Med Sci Sports Exerc 50:551-561
Zhang, Lijun; Wang, Ming; Sterling, Nicholas W et al. (2018) Cortical Thinning and Cognitive Impairment in Parkinson's Disease without Dementia. IEEE/ACM Trans Comput Biol Bioinform 15:570-580
Rossi, Alexander; Berger, Kristin; Chen, Honglei et al. (2018) Projection of the prevalence of Parkinson's disease in the coming decades: Revisited. Mov Disord 33:156-159
Lee, Soomi; Martire, Lynn M; Damaske, Sarah A et al. (2018) Covariation in couples' nightly sleep and gender differences. Sleep Health 4:201-208
Almeida, David M; Lee, Soomi; Walter, Kimberly N et al. (2018) The effects of a workplace intervention on employees' cortisol awakening response. Community Work Fam 21:151-167
Liu, Guodong; Sterling, Nicholas W; Kong, Lan et al. (2017) Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database. Mov Disord 32:913-917
Sterling, Nicholas W; Du, Guangwei; Lewis, Mechelle M et al. (2017) Cortical gray and subcortical white matter associations in Parkinson's disease. Neurobiol Aging 49:100-108
Berryman, Claire E; Fleming, Jennifer A; Kris-Etherton, Penny M (2017) Inclusion of Almonds in a Cholesterol-Lowering Diet Improves Plasma HDL Subspecies and Cholesterol Efflux to Serum in Normal-Weight Individuals with Elevated LDL Cholesterol. J Nutr 147:1517-1523
Calhoun, Susan L; Fernandez-Mendoza, Julio; Vgontzas, Alexandros N et al. (2017) Behavioral Profiles Associated with Objective Sleep Duration in Young Children with Insomnia Symptoms. J Abnorm Child Psychol 45:337-344
Lewis, Mechelle M; Flynn, Michael R; Lee, Eun-Young et al. (2016) Longitudinal T1 relaxation rate (R1) captures changes in short-term Mn exposure in welders. Neurotoxicology 57:39-44

Showing the most recent 10 out of 645 publications